Compare PROF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.7M | 322.1M |
| IPO Year | 2017 | 2019 |
| Metric | PROF | BNR |
|---|---|---|
| Price | $7.48 | $23.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 145.3K | 10.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $10,680,000.00 | N/A |
| Revenue This Year | $61.09 | $136.32 |
| Revenue Next Year | $120.94 | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | ★ 48.35 | N/A |
| 52 Week Low | $3.90 | $2.18 |
| 52 Week High | $8.95 | $41.72 |
| Indicator | PROF | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 36.81 |
| Support Level | $5.31 | $19.10 |
| Resistance Level | $7.95 | $24.23 |
| Average True Range (ATR) | 0.42 | 1.77 |
| MACD | 0.10 | -0.93 |
| Stochastic Oscillator | 75.38 | 5.24 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.